Depemokimab significantly reduces asthma exacerbations, benefiting patients regardless of their baseline asthma control levels. A biologics license application for depemokimab is currently being ...

GSK, which also has phase 3 programmes running for depemokimab in EGPA and HES, has previously put a target peak sales figure of £3 billion ($3.9 billion) a year on the drug.

GSK stock is up 21.5% in six months, fueled by strong Specialty Medicines growth and a promising pipeline despite vaccine headwinds.

GSK's long-acting drug antibody for severe asthma, depemokimab, cut the rate of attacks by 54% in phase 3 trials presented at ERS.

Managed Healthcare Executive gives C-suite executives in health plans and provider organizations news and strategies for value-driven solutions.

Depemokimab targets interleukin-5 (IL-5), which plays a crucial role in type 2 inflammation. GSK’s submission is supported by the positive Phase III SWIFT and ANCHOR trial data.

After nearly 25 years with Sanofi, Sanjay Gurunathan, M.D., has left for GSK, where he will lead vaccine and infectious disease R&D for the British pharma. | After nearly 25 years with Sanofi ...